Kyongbo Pharmaceutical Co. Ltd. | Mutual Funds
Mutual Funds that own Kyongbo Pharmaceutical Co. Ltd.
DFA Emerging Markets Core Equity Portfolio
115,440
0.48%
22,006
0.01%
04/30/2018
DFA Emerging Markets Small Cap Series
95,168
0.4%
0
0.02%
01/31/2018
CREF Stock Account
59,520
0.25%
0
0%
03/31/2018
Mirae Asset TIGER Health Care ETF
18,342
0.08%
4,397
0.14%
04/30/2018
iShares III Plc - MSCI Emerging Markets Small Cap
6,688
0.03%
0
0.02%
09/05/2018
5,206
0.02%
3,171
0.03%
04/30/2018
DFA Emerging Markets Social Core Equity Portfolio
4,877
0.02%
0
0%
04/30/2018
DFA World (ex-US) Core Equity Portfolio
2,380
0.01%
1,494
0%
04/30/2018
John Hancock II - Emerging Markets Fund
1,922
0.01%
0
0%
04/30/2018
Dimensional Funds ICVC - Emerging Markets Core Equity Fund
1,888
0.01%
0
0%
12/31/2017
| Address |
174 Sirok-ro
Asan SC 31501
Korea, Republic Of
|
|
Employees
|
- |
| Website |
http://www.kbpharma.co.kr |
| Updated |
07/08/2019 |
| KYONGBO PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include general, antibiotic, anticancer active pharmaceutical ingredients, inhalation anesthetic, cefaclor capsule and cefaclor dried syrup. The company was founded on March 31, 1987 and is headquartered in Asan, South Korea. |
